BAY-1862864

N/A

Report date: 2025/10/20 14:43:29

Base Information

Drug NameBAY-1862864

Drug Alias Name227Th-epratuzumabBAY-1862864BAY 1862864

ClassificationRadiation-emitting products > Nuclides > Thorium > 227ThRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionCD22 modulators

TargetsCD22

Therapy Area/IndicationsLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwedenUnited Kingdom

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBayer AG

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBayer AG

Active IndicationsN/A

Inactive IndicationsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A